|
| 奥拉帕利、贝伐珠单抗联合铂类化疗方案治疗卵巢癌的临床研究 |
| Clinical study of olaparil, bevacizumab and platinum chemotherapy regimen for ovarian cancer |
| 投稿时间：2024-07-08 修订日期：2024-07-12 |
| 中文关键词: 卵巢癌 奥拉帕利 贝伐珠单抗 铂类化疗 近期疗效 血管内皮相关因子 |
| 英文关键词: ovarian cancer olaparil bevacizumab platinum-based chemotherapy recent efficacy vascular endothelium-related factors |
|
| 摘要点击次数: 38 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨奥拉帕利、贝伐珠单抗联合铂类化疗方案治疗卵巢癌的临床研究。方法 选取联勤保障部队第九八九医院2021年7月~2024年1月期间收治的卵巢癌患者90例，利用倾向性评分匹配法按1:1比例匹配后得到研究组和对照组各45例。对照组给予贝伐珠单抗联合顺铂、紫杉醇化疗，研究组在此基础上给予奥拉帕利片口服治疗，均治疗4个疗程。比较两组客观缓解率（ORR）和治疗前后血清血管生成素-2（Ang-2）、血管内皮生长因子（VEGF）、人附睾蛋白4（HE4）、免疫指标水平和用药期间药毒副反应发生率。结果 研究组ORR为68.89%，高于对照组的44.44%（P＜0.05）；治疗后，研究组VEGF、Ang-2和HE4水平均显著低于对照组（P＜0.05）；研究组CD3+、CD4+和CD4+/CD8+高于对照组（P＜0.05）；两组各项毒副反应发生率均无显著差异（P＞0.05）。结论 奥拉帕利、贝伐珠单抗联合铂类化疗治疗可有效提高卵巢癌患者近期疗效，改善血管内皮相关因子和免疫功能指标水平，安全性尚可控。 |
| 英文摘要: |
| Objective To investigate the clinical study of olaparil and bevacizumab combined with platinum chemotherapy for ovarian cancer. Methods A total of 90 ovarian cancer patients admitted to JSA 989 Hospital from July 2021 to January 2024 were selected and 45 from the study group and control group. The control group was given bevacizumab combined with cisplatin and paclitaxel chemotherapy, and the study group was given olapalil tablets orally, all for four courses. Objective response rates (ORR) and pre-and post-treatment serum angiogenin-2 (Ang-2), vascular endothelial growth factor (VE GF), human epididymal protein 4 (HE4), immune index level, and the incidence of toxic side effects during medication were compared. Results The ORR of the study group was 68.89%, higher than the control group of 44.44% (P <0.05); after treatment, VE GF, Ang-2, and HE4 were significantly lower than the study group (P <0.05); CD3 +, CD4 + and CD4 + / CD8 + were higher than the study group (P <0.05); the incidence of the two groups was not different (P> 0.05). Conclusion Olaapil and bevacizumab combined with platinum chemotherapy can effectively improve the recent efficacy of ovarian cancer patients, improve the level of endothelium-related factors and immune function indicators in blood vessels, and the safety is controllable. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
